Whitehawk Therapeutics Inc (WHWK)
NASDAQ
Healthcare
Biotechnology
$4.67
▲ +2.64%
Market Cap
$266.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.78
52-Wk Range
1.57-5.495
CEO
David J. Lennon
Country
US
Currency
USD
Whitehawk Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Morristown, NJ, US. The stock last traded at $4.67, up 2.64% on the session, giving a market capitalisation of $266.2M. On trailing twelve-month figures it carries a trailing P/E of -4.17, a net margin of 0.0%. Its beta of 0.78 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-4.17
Price / Sales
0.00
Price / Book
2.12
EV / EBITDA
-2.23
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
17.38
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
23
IPO date
2017-08-01
Headquarters
Morristown, NJ, US
About Whitehawk Therapeutics Inc
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Comparable companies
Whitehawk Therapeutics Inc is most often compared with the following Healthcare names:
More research on WHWK
Open full interactive analysis & DCF →